1. Analysis of completed reconstructive cosmetic surgery interface fellowships in the UK. (October 2015) Authors: Gurney, B.; Johnson, P. Journal: International journal of oral & maxillofacial surgery Issue: Volume 44(2015)Supplement 1 Page Start: e75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DEFINING BURKITT‐LIKE LYMPHOMA WITH 11Q ABERRATION IN A SPECIALISED UK HAEMATOPATHOLOGY DIAGNOSTIC SERVICE. (12th June 2019) Authors: Barrans, S.; Painter, D.; van Hoppe, S.; Smith, A.; Sha, C.; Cucco, F.; Du, M.; Westhead, D.; Davies, A.; Johnson, P.; Roman, E.; Burton, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B‐CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL. (12th June 2019) Authors: Balasubramanian, S.; Wang, S.; Major, C.; Hodkinson, B.; Schaffer, M.; Sehn, L.H.; Johnson, P.; Zinzani, P.L.; Carey, J.; Liu, G.; Loefgren, C.; Shreeve, M.; Sun, S.; Zhuang, S.; Vermeulen, J.; Staudt, L.M.; Younes, A.; Wilson, W. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) Authors: Cummin, T.E.; Caddy, J.; Mercer, K.; Maishman, T.; Schuh, A.; Lopez Pascua, L.; Collins, G.; McMillan, A.; Ardeshna, K.; Galanopoulous, A.; Burton, C.; Barrans, S.; Griffiths, G.; Johnson, P.; Davies, A.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. LONGITUDINAL ANALYSES OF DIAGNOSTIC‐RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. (12th June 2019) Authors: Korfi, K.; Araf, S.; Bewicke‐Copley, F.; Kumar, E.; Cummin, T.; Ashton‐Key, M.; Barrans, S.; Van Hoppe, S.; Burton, C.; Elshiekh, M.; Rule, S.; Crosbie, N.; Clear, A.; Calaminici, M.; Menon, G.; Sha, C.; Bentley, M.; Nagano, A.; Davies, A.; Painter, D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY. (12th June 2019) Authors: Davies, A.J.; Tansley Hancock, O.; Cummin, T.; Caddy, J.; Stanton, L.; Burton, C.; Barrans, S.; Coleman, A.; Osborne, W.; McKay, P.; Griffiths, G.; Johnson, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. HIGH EXPRESSION OF BCL‐2 AND BCL‐XL IN DIFFUSE LARGE B‐CELL LYMPHOMA CONFER POOR PROGNOSIS BUT MAY BE REVERSIBLE BY COMBINED INHIBITION WITH BET INHIBITORS AND BH3 MIMETICS. (12th June 2019) Authors: Cummin, T.E.; Cox, K.; Murray, T.; Barrans, S.; Sha, C.; Westhead, D.; Burton, C.; Davies, A.; Cragg, M.; Johnson, P.; Carter, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. APPLICATION OF a GENE EXPRESSION‐BASED MODEL IN COMBINATION WITH FDG‐PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033). (June 2017) Authors: Burton, C.H.; Scott, D.; Kirkwood, A.A.; Gandhi, M.; Radford, J.; Barrington, S.; Federico, M.; Luminari, S.; Trotman, J.; Berkhan, L.; D'Amore, F.A.; Kamp, P.; Enblad, G.; Molin, D.; Chalkley, R.; Smith, P.; Stevens, L.; Roberts, T.; Patrick, P.; Chan, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS. (June 2017) Authors: Morschhauser, F.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Johnson, P.; Le Gouill, S.; Dickinson, M.J.; Fruchart, C.; Lamy, T.; Chaidos, A.; Jurczak, W.; Opat, S.; Radford, J.; Zinzani, P.L.; Assouline, S.; Cartron, G.; Clawson, A.; Picazio, N. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. CHOP VERSUS GEM‐P IN THE FIRST‐LINE TREATMENT OF T‐CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO‐T TRIAL. (June 2017) Authors: Gleeson, M.; Peckitt, C.; To, Y.M.; Edwards, L.; Chau, I.; Johnson, P.; Ardeshna, K.M.; Wotherspoon, A.; Attygalle, A.; Begum, R.; Chua, S.; Zerizer, I.; Hawkes, E.A.; Macheta, M.P.; Collins, G.P.; Radford, J.A.; Forbes, A.; Hart, A.; Montoto, S.; McKay, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗